Baseline molecular profiling was often mandatory in patients with non-squamous histology to exclude tumours that harbored an alteration in EGFR or ALK genes, while other more rare molecular alterations were not mentioned in the eligibility criteria. The gene discussed is ALK; the disease is neoplasm.